Intelect Medical is developing technologies for deep brain stimulation (DBS) therapy and Boston Scientific (BoSci) values the target at $78m.
New York-listed medical device maker Boston Scientific has paid $60m to buy the remainder of Intelect Medical, one of its corporate venturing unit’s portfolio companies.
As a result of Boston Scientific’s existing equity and debt positions in Intelect Medical, the total cash payment by Boston Scientific was $18m less than the target’s enterprise value.
Intelect Medical is developing technologies for deep brain stimulation (DBS) therapy and Boston Scientific values the target at $78m.
Boston Scientific estimates the…
